FGF-2 exerts its pleiotropic effects on cell growth and differentiation by interacting with specific cell surface receptors. In addition, exogenously added FGF-2 is translocated from outside the cell to the nucleus during G1-S transition. In this study, we show that a single point mutation in FGF-2 (substitution of residue serine 117 by alanine) is sufficient to drastically reduce its mitogenic activity without affecting its differentiation properties. The FGF-2(S117A) mutant binds to and activates tyrosine kinase receptors and induces MAPK and p70S6K activation as strongly as the wild-type FGF-2. We demonstrate that this mutant enters NIH3T3 cells, is translocated to the nucleus, and is phosphorylated similar to the wild-type growth factor. This suggests that FGF-2 mitogenic activity may require, in addition to signaling through cell surface receptors and nuclear translocation, activation of nuclear targets. We have previously shown that, in vitro, FGF-2 directly stimulates the activity of the casein kinase 2 (CK2), a ubiquitous serine/threonine kinase involved in the control of cell proliferation. We report that, in vivo, FGF-2(WT) transiently interacts with CK2 and stimulates its activity in the nucleus during G1-S transition in NIH3T3 cells. In contrast, the FGF-2(S117A) mutant fails to interact with CK2. Thus, our results show that FGF-2 mitogenic and differentiation activities can be dissociated by a single point mutation and that CK2 may be a new nuclear effector involved in FGF-2 mitogenic activity.-Bailly, K., Soulet, F., Leroy, D., Amalric, F., Bouche, G. Uncoupling of cell proliferation and differentiation activities of basic fibroblast growth factor (FGF-2). FASEB J. 14, 333-344 (2000)
important role in cell growth and differentiation, neurite outgrowth, embryogenesis, angiogenesis, and wound healing (3) . FGF-2 exists as four molecular forms including three of high molecular mass (21.5, 22 , and 24 kDa) initiated by alternative CUGcodon, and one 18 kDa form initiated at canonical AUG codon (4, 5) . In cells that produce FGF-2, the higher molecular mass isoforms are found exclusively in the nucleus, whereas the 18 kDa FGF-2 is cytoplasmic, excreted and stored in the extracellular matrix (6, 7) . The pleiotropic effects in cell growth and differentiation exhibited by 18 kDa FGF-2 reflect an intricate combinatorial process involving potential interactions between the growth factor, four different high-affinity transmembrane tyrosine kinase receptors (FGF-R1 to R4), and low-affinity binding sites corresponding to the naturally heterogeneous glycosaminoglycan chains of heparan sulfate proteoglycans (HSPG) (1, 8) . The functional domain of FGF-2 (18 kDa, 155 amino acid form) that participates in heparin binding is composed of extended array of positively charged lysine and arginine residues (9 -12) . In addition, Springer et al. identified high-and low-affinity receptor binding surfaces on FGF-2 on the basis of site directed mutagenesis and molecular modeling (13) . Using a molecular modeling method, Lam et al. (14) recently proposed a modeled complex between heparin, FGF-2, and FGF-R1 with a 1: 2: 2 stochiometry consistent with the reported site-specific mutagenesis and biochemical cross-linking data.
FGF-2 binding to its receptor causes its autophosphorylation and activation of at least two signaling pathways, mitogen-activated protein kinase (MAPK) and phospholipase C-␥ (PLC␥), leading to mitogenic response (15) . The MAPK pathway is required for proliferation of fibroblasts in culture (16) , for neurotrophic growth factor (NGF)-and epidermal growth factor (EGF) -induced differentiation of PC12, and for transformation of NIH3T3 (17) . In contrast, PLC␥ is not involved in FGF-mediated mitogenesis in L6 myoblast and BaF3 cells or in differentiation of PC12 cells (18 -20) .
In addition to these classical signal transduction pathways, some of the mitogenic signals may be provided by FGFs themselves. Indeed, exogenous FGF-1 and FGF-2 (18 kDa) are translocated from outside the cell to the nucleus (21, 22) . For FGF-1, this nuclear localization is necessary for mitogenic activity (23) (24) (25) whereas the nuclear translocation and accumulation of FGF-2 in the nucleolus are associated with cellular proliferation (22, 26) . Addition of FGF-2 to nuclei isolated from G0-arrested ABAE cells induced an increase of phosphorylation of nuclear proteins (27) . One of them-nucleolin-an important component of the nucleolus, is also a major substrate for protein kinase CK2 in rapidly proliferating tissues (28) . The direct interaction of FGF-2 in vitro with CK2 stimulates CK2 activity (29) and suggests that CK2 could be a downstream effector of the mitogenic signaling pathway induced by exogenously added FGF-2.
CK2, which is present in the cytoplasm and nucleus of all eukaryotic cells, is composed of two catalytic ␣ and/or ␣' subunits and two regulatory ␤ subunits, and phosphorylates a large number of proteins (30) . In yeast, CK2 is essential for viability (31) . In mammalian cells, CK2 is required for cell cycle progression (32, 33) and associates with several growth-related proteins including p53 (34) , IB-␣ (35), and c-Mos (36, 37) .
To gain new insight into the FGF-2-induced mitogenic signaling pathway, we analyzed the biological properties of FGF-2 mutants. We show that the mitogenic and differentiation activities of FGF-2 can be dissociated by the mutation of serine 117; FGF-2(S117A) is a poor inducer of proliferation, but possess an intact differentiation activity. Signal transduction through high-affinity receptors and nuclear translocation are not affected by this mutation. However, whereas FGF-2(WT)/CK2 complexes are detected in the nucleus and cytoplasm during the G1/S transition, FGF-2(S117A) is not found to be associated with CK2. In addition, we show that in early G 1 phase, FGF-2(WT) seems to specifically stimulate CK2 in the nucleus whereas FGF-2(S117A) is inactive. These results suggest that FGF-2 mitogenic signal transduction pathway requires, in addition to signaling through cell surface receptors, activation of the protein kinase CK2 within the nucleus at the early G 1 phase.
MATERIALS AND METHODS

Plasmid construction, protein purification, and biotinylation
The human FGF-2 cDNA was subcloned into the SmaI/XbaI sites of the vector pGEX-KG (38) . FGF-2(R116A), FGF-2(S117A), FGF-2(R118A), FGF-2(K119A), FGF-2(K119E), FGF-2(Y120F), and FGF-2(T121A) cDNAs were prepared by polymerase chain reaction using a primer containing the mutated base. FGF-2(WT), FGF-2(R116A), FGF-2(S117A), FGF-2(R118A), FGF-2(K119A), FGF-2(K119E), FGF-2(Y120F), and FGF-2(T121A) proteins were expressed and purified as described by the manufacturer's instructions (Pharmacia Biotech, Brussels, Belgium) except that they were further purified using a heparin Sepharose CL6-B column (Pharmacia Biotech). The concentration of NaCl that eluted the FGF-2(S117A) mutant from heparin (1.3 M) was the same as that which eluted FGF-2(WT). The GST carrier was removed from fusion proteins by cleavage with 25 units of thrombin (Pharmacia Biotech) in 500 l phosphate-buffered saline (PBS). The nucleolin purification and protein biotinylation were performed as described previously (29) . Biotinylation on cystein residues of FGF-2 does not affect its biological activity (39) .
Competition of the interaction between CK2 and [ 3 H]spermine and biotinylated-FGF-2 binding to CK2 in vitro
Competition assays were based on a previous study (40) . Seven to fifteen pmoles of CK2, 20 pmol of tritiated spermine (1 Ci), and 1 M of FGF-2 peptides (generously provided by A. Baird) were incubated at 4°C for 5 min in a final volume of 80 l, with a final concentration of 10 mM Tris, pH 7.4. Then samples were loaded onto a Sephadex G-50 column (Pharmacia). After a centrifugation for 3 min at 2000 ϫ g at 4°C, the eluent, containing CK2-[ 3 H]spermine and CK2-FGF-2 or CK2-FGF-2 peptides, was collected. [ 3 H]spermine bound to CK2 was determined by scintillation counter.
Biotinylated-FGF-2/CK2 ␤ subunit reactions were achieved as described previously (29) with nuclear extracts prepared from insect cells overexpressing Drosophila melanogaster ␤ subunit of CK2.
Cell culture
NIH3T3 and ABAE (adult bovine aortic endothelial) cells were propagated in DMEM (Life Technologies, Inc., Grand Island, N.Y.) containing antibiotics and supplemented with 10% FCS (fetal calf serum) and 10% CS (calf serum), respectively. [ 3 H]Thymidine incorporation was measured as described (24, 26) . BHK-21 (baby hamster kidney clone 21) cells were grown in DMEM-F12 medium supplemented with 5% FCS and antibiotics. The rat bladder carcinoma NBT-II and transfected FGF-R1 NBT-II (NBT-II.R1) cells obtained from Dr. J. Jouanneau (Laboratoire de Physiopathologie du Développement, C.N.R.S.-Ecole Normale Supérieure, Paris, France) and PC12 cells were cultured in DMEM supplemented with antibiotics and 10% FCS. Emfi fgf-2 Ϫ/Ϫ or Emfi fgf-2 ϩ/ϩ cells, a generous gift of Dr. T. Doetschman (University of Cincinnati College of Medicine, Cincinnati, Ohio) (41), were propagated as described above for NIH3T3.
A dose response experiment allowed us to determine the optimal concentration of FGF-2(WT) and FGF-2(S117A) for PC12 and NBTII or NBT-II.R1 cell differentiation. PC12 cells grown to low confluency in 24-well plates in standard medium were stimulated with 10 ng/ml FGF-2(WT) or FGF-2(S117A) for 3 days. NBT-II or NBT-II.R1 cells grown to low confluency in 24-well plates in standard medium were activated for 3 days with 5 ng/ml FGF-2(WT) or FGF-2(S117A).
Cross-linking and binding of 125 I-labeled FGF-2(WT) or FGF-2(S117A) to BHK-21 cells
Purified proteins were radioiodinated using chloramine Timmobilized on nonporous polystyrene beads (IODO-BEADS from Pierce Chemical Co., Rockford, Ill.) according to the manufacturer's instructions. Protein-bound and free iodide were separated by centrifugation with microconcentrators 10, with a cutoff of 10 kDa (Amicon, Beverly, Mass.). The specific activity of the iodinated proteins was routinely ϳ5 ϫ 10 5 cpm/ng of protein. The cross-linking and binding were performed as described previously (42) . Cross-linking products were analyzed by Western blotting using an anti-streptavidin peroxidase antibody (Amersham, Amersham, U.K.).
Subcellular localization of FGF-2 by immunofluorescence microscopy
The immunofluorescence microscopy was achieved as described previously (26) with some modifications. NIH3T3 cells were grown on glass coverslips, fixed with 3% paraformaldehyde in PBS for 15 min at 4°C, and washed with PBS-0.5% bovine serum albumin (BSA) (2ϫ5 min) and then with 50 mM NH 4 Cl in PBS at 4°C for 20 min. The fixed cell monolayers were permeabilized with 0.1% Triton X-100 in PBS for 5 min at 20°C, washed twice with PBS, and twice with PBS-0.5% BSA at 4°C. Treated coverslips were incubated at 37°C for 1 h with the anti-human FGF-2 monoclonal antibody (Transduction Laboratories, Lexington, Ky.) diluted 1/30 in PBS-0.5% BSA. After three washes with PBS-0.5% BSA, cells were further incubated for 1 h at 37°C with fluoresceinconjugated goat anti-mouse IgG (Immunotech) diluted 1/40 in PBS-0.5% BSA. Finally, the coverslips were washed with PBS-0.5% BSA (2ϫ5 min) and with PBS alone (2ϫ5 min), then air dried and mounted in Mowiol. Fluorescence of fixed immunostained cells was viewed with a Zeiss confocal laser scanning using a 63ϫ oil immersion objective.
Purification and subcellular localization of biotinylated FGF-2/CK2 complexes NIH3T3 or PC12 cells were seeded in 100 mm dishes at a density of 10 5 cells/dish. After 72 h, NIH3T3 cells were G0-arrested by serum starvation for 1 day. Cells were then either untreated or stimulated with biotinylated FGF-2(WT) or biotinylated FGF-2(S117A) for different times. Conditioned culture medium was recovered and the cells were washed twice in PBS containing mixture of protease inhibitors (Boehringer Mannheim, Mannheim, Germany). After trypsinization, the cells were harvested in 5 ml of DMEM-10% FCS, centrifuged for 5 min at 600 ϫ g at 4°C, and washed twice in PBS. The cells were disrupted for 1-2 min by gentle homogenization in 1 ml of lysis buffer containing 15 mM Tris, pH 7.5, 150 mM NaCl, 5 mM MgCl 2 , 0.1% Tween 20, 0.3% NP10, and a mixture of protease inhibitors. Nuclear and postnuclear fractions were prepared as described previously (43) . Conditioned culture medium, total extract, or nuclear and postnuclear extracts were incubated in the presence of streptavidin beads for 60 min at 4°C under constant rotation. After extensive washing, bound proteins were directly resuspended in 1ϫ Laemmli sample buffer and analyzed by Western blotting using anti-FGF-2 (Sigma, St. Louis, Mo.), anti-CK2 ␣ (UBI), and anti-CK2 ␤ (Calbiochem, Nottingham, U.K.) antibodies.
Nucleolin and tyrosine phosphorylation assays; MAPK activation
Phosphorylation assays were achieved as described previously (29) ; nuclear or cytoplasmic extracts were prepared from NIH3T3 cells stimulated with FCS, FGF-2(WT), or FGF-2(S117A). All reactions were stopped by adding 6 l TCA. The resulting TCA-insoluble material was mixed with 20 l of 1ϫ Laemmli sample buffer. Phosphorylation levels were normalized relative to the quantity of catalytic ␣ subunit of CK2 in nuclear and cytoplasmic extracts by performing immunoblotting experiments with an anti-CK2 ␣ antibody (data not shown).
For tyrosine phosphorylation and MAPK activation detection, NIH3T3, Emfi fgf-2 Ϫ/Ϫ, or Emfi fgf-2ϩ/ϩ cells growing in 100 mm dishes were kept for 1 day in medium containing 0% FCS. Subsequently, cells were untreated or stimulated with 20 ng/ml FGF-2(WT) or FGF-2(S117A) for the times indicated. The cells were washed twice in PBS containing 100 M sodium orthovanadate, 30 mM sodium pyrophosphate, 50 mM NaF as phosphatase inhibitors, and a mixture of protease inhibitors and lysed in 15 mM Tris, pH 8, 150 mM NaCl, 2 mM MgCl 2 , 0.5% Tween 20, 1% Triton X-100 supplemented with protease and phosphatase inhibitors, as described above. After centrifugation, supernatants were trichloroacetic acid precipitated and resuspended in 1ϫ Laemmli sample buffer. Tyrosine phosphorylation and activation of endogenous extracellular signal-regulated kinase (ERK) were measured by Western blotting using an antiphosphotyrosine monoclonal antibody (UBI) and an anti-active ERK antibody (Promega, Southampton, U.K.), respectively. Total endogenous ERK was detected with an anti-ERK antibody (New England Biolabs, Beverly, Mass.).
p70 S6 kinase activity assay
The p70S6K activity assay was performed as described previously (44) with some modifications. G0-arrested NIH3T3 cells cultured on 100 mm dishes were either unstimulated or stimulated with 20 ng/ml FGF-2(WT) or FGF-2(S117A) for 60 min. Cells were washed with extraction buffer (EB) containing in 50 mM Tris, pH 8, 120 mM NaCl, 20 mM NaF, 30 mM 4-nitrophenyl phosphate, 0.1 mM PMSF, 1 mM EDTA, 6 mM EGTA, 15 mM Na 4 P 2 O 7 . After washing, cells were lysed in EB containing 1% Nonidet P-40 on ice. Collected cell lysate was frozen in liquid nitrogen and kept at Ϫ80°C until assay. After thawing, the lysate was centrifuged at 10,000 ϫ g for 30 min and then 100 g of lysed protein was incubated with 7.5 g of an anti-p70S6K monoclonal antibody (Calbiochem) at 4°C for 3 h, followed by precipitation with 20 l of 50% (wet v/v) protein A-Sepharose beads for 1 h. The protein A immune complex was collected by centrifugation, washed three times with EB containing Nonidet P-40, once with dilution buffer (DB: 50 mM MOPS, pH 7.2, 5 mM MgCl 2 , 1 mM DTT), and resuspended in 10 l of DB. The p70S6K activity was measured with a S6 Kinase assay kit (UBI) according to the manufacturer's instructions. Quantities of immunoprecipitated p70S6K were verified by performing immunoblotting experiments with an anti-p70S6K antibody.
In vivo FGF phosphorylation
The in vivo phosphorylation assay was performed as described previously (45) with some modifications. G0-arrested NIH3T3 were preincubated at 37°C for 3 h in phosphate-free DMEM containing 100 Ci/ml 32 PO 4 3-. Biotinylated FGF-2(WT) or FGF-2(S117A) (20 ng/ml) was added and the incubation was continued for 12 h. The cells were washed twice in PBS and lysed in 15 mM Tris, pH 7.5, 150 mM NaCl, 5 mM MgCl 2 , 0.1% Tween 20, 0.3% NP10 supplemented with phosphatase and protease inhibitors. Nuclear and postnuclear fractions were prepared as described previously (43) and incubated in the presence of streptavidin beads for 60 min at 4°C under constant rotation. After extensive washing, bound proteins were directly resuspended in 1ϫ Laemmli sample buffer and analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and autoradiography.
RESULTS
Mutation S117A in FGF-2 strongly reduced its mitogenic activity without affecting its differentiation properties
We have previously shown that FGF-2 interacts with the regulatory ␤ subunit of the protein kinase CK2 in vitro and stimulates its activity on specific nuclear substrates such as nucleolin (29), a natural substrate of this enzyme involved in ribosome biogenesis (46, 47) . CK2 is stimulated in vitro by polycation structures, including polyamines such as spermine (30, 48, 49) . CK2 interacts with spermine through its regulatory ␤ subunit (49) . Using FGF-2 and synthetic peptides spanning the entire sequence of FGF-2, we have performed competition of the interaction between CK2 and [ 3 H]spermine. We showed that FGF-2 displaced [
3 H]spermine and that the 115-129 amino acid sequence of FGF-2 was critical for the interaction with CK2 (Fig. 1A) . To identify the residues on FGF-2 important for both CK2 binding and FGF-2 biological properties, several mutations within this region 115-129 were performed (Fig.  1B ). All these mutants were first tested for the binding to CK2 in vitro and then for mitogenic and differentiation activities. Only one showed interesting characteristics and is described in this paper. Added to baculovirus-infected cell extracts overexpressing ␤ subunits of CK2, FGF-2(S117A) (in which serine 117 was substituted by alanine) had an impaired ability to interact with the ␤ regulatory subunit of CK2 (Fig. 1C) and to stimulate CK2 activity using nucleolin as substrate (data not shown) compared to wild-type FGF-2.
Moreover, this mutant had a greatly reduced mitogenic activity (defined as the ability of a cell to undergo S phase) compared to FGF-2(WT) in NIH3T3 and ABAE cells. The maximal mitogenic activity of wild-type FGF-2 is observed at 10 ng/ml and 1 ng/ml for NIH3T3 and ABAE cells, respectively ( Fig. 2A) . FGF-2(S117A) was unable to promote mitogenicity at these concentrations and presented a mitogenic activity reduced by 80% compared to that of wild-type growth factor at 20 ng/ml for NIH3T3 cells. We then tested the differentiation properties of FGF-2(S117A) (Fig. 2B) . First, neuronal differentiation in the PC12 phaeochromocytoma cell line by FGF-2(WT) and FGF-2(S117A) was analyzed (50) . Similar to FGF-2(WT), FGF-2(S117A) promoted neurite outgrowth in PC12 cells at the same concentration (Fig. 2B, left panel) . Then the induction of the epithelial-mesenchymal transition (EMT) in untransfected or FGF-R1 transfected bladder carcinoma cells (NBTII and NBTII.R1, respectively) was examined (Fig. 2B , medium and right panels). NBT-II and NBT-II.R1 formed epithelial cell clusters in standard culture medium (CT). As expected, FGF-2(WT) was able to induce the EMT in NBTII.R1 but not in untransfected NBTII cells (51) . Similar to wild-type FGF-2, the FGF-2(S117A) mutant caused NBTII.R1 to lose their epithelial character and to acquire the mesenchymal phenotype leading to cell dissociation. Together, these results demonstrate that the mitogenic and differentiation activities of FGF-2 can be uncoupled by a single point mutation (S117A) that affects the binding to CK2 in vitro.
FGF-2(S117A) binds to and activates FGF receptors
FGF-mediated activities require binding of the growth factor to its high-affinity tyrosine kinase re- (Fig. 3A, Insert) . We revealed a complex of approximately M r 140,000 corresponding to those of FGF-2 (18 kDa) and FGF-R (125 kDa). Therefore, both FGF-2(WT) and FGF-2(S117A) bound to FGF receptors. To test whether FGF-2(S117A) competed with FGF-2(WT) for similar binding sites, the ability of increasing concentrations of FGF-2(WT) and FGF-2(S117A) to displace 125 I-FGF-2(WT) or 125 I-FGF-2(S117A) bound to cell surface receptors was analyzed. As shown Fig. 3A , both FGF-2(WT) and FGF-2(S117A) displaced wild-type or mutated FGF-2 with the same efficiency. This shows that both FGF-2(WT) and FGF-2(S117A) can compete for similar binding sites with equivalent affinities. To study whether the mutant retained the ability to activate FGF receptors, we tested its effect on tyrosine phosphorylation of cellular proteins in NIH3T3 cells (Fig. 3B ). As shown in Fig. 3B , the pattern of total protein tyrosine phosphorylation after treatment with mutant FGF-2 for various time periods was similar to that obtained after wild-type growth factor stimulation. Both wild-type and mutated FGF-2 induced transient (up to 30 min) tyrosine phosphorylation of cellular proteins. This demonstrates that FGF-2(S117A) retains the ability to interact with and stimulate the FGF receptors in the cells.
FGF-2-binding to cell surface receptors has been shown to initiate at least two signaling pathways leading to mitogenic response through activation of MAPK and PLC␥ (15) . By immunoblotting experiments with antibodies raised against phosphorylated forms of MAPK, we observed, after a short (up to 1 h) or a long (from 1 h to 12 h) stimulation, that FGF-2(S117A) mutant was able to activate MAPK as FGF-2(WT) in NIH3T3 cells (Fig. 4A) . No activation of PLC␥ was detected in FGF-2(WT) and FGF-2(S117A)-stimulated NIH3T3 cells, suggesting that this enzyme is not involved in FGF-2-induced mitogenic signal transduction pathway in this cell line (data not shown). In addition, it was shown that p70 S6 kinase, a serine/threonine kinase that phosphorylates 40 S ribosomal protein S6 in response to a number of extracellular stimuli (44) , is required for FGF-stimulated cell proliferation but not for differentiation of endothelial cells (44) . p70S6K activation was examined by immunoprecipitation of p70S6K from unstimulated and wild-type or mutated FGF-2-stimulated NIH3T3 cells, followed by incubation in kinase buffer and [␥- 32 P]ATP in the presence of synthetic peptides, serving as a substrate for immunoprecipitated p70S6K. Figure 4B shows that p70S6K is activated in a similar manner in FGF-2(WT) and FGF-2(S117A)-stimulated cells. These results indi- Figure 2 . FGF-2(S117A) has a strongly reduced mitogenic activity but intact differentiation properties. A) G0-arrested NIH3T3 and ABAE cells were stimulated for 24 and 8 h, respectively, by different concentrations of FGF-2(WT) (ࡗ) or FGF-2(S117A) (OE). [ 3 H]Thymidine was added in NIH3T3 and ABAE cultures for the last 8 h and 4 h, respectively, then incorporated radioactivity was measured. B) PC12 cells were unstimulated (CT) or stimulated with 10 ng/ml FGF-2(WT) and FGF-2(S117A). Neurite outgrowth was observed 3 days after growth factor treatment. Low confluency NBT-II or FGF-R1-transfected NBT-II (NBT-II.R1) was unstimulated (CT) or stimulated with 5 ng/ml FGF-2(WT) and FGF-2(S117A). Cell dissociation reflecting the epithelial-mesenchymal transition was observed 3 days after growth factor treatment.
cate that FGF-2(S117A) triggers the activation of the main signaling pathway involved in mitogenic response, MAPK and p70S6K.
The low levels of FGF-2 synthesized in NIH3T3 cells are excreted (52, 53) and accumulated in the extracellular matrix (6, 7) . It is therefore possible that FGF-2(S117A) could indirectly induce the activation of MAPK through the release of FGF-2 stored in extracellular matrix. To exclude this possibility, we evaluated the effects of FGF-2(S117A) in fgf-2 gene-ablated embryonic fibroblasts (41) (Emfi fgf-2 Ϫ/Ϫ cells). In these cells, the patterns of FGF-2(WT) and FGF-2(S117A)-induced MAPK activation kinetics were the same (Fig.  4C) . In Emfi fgf-2 Ϫ/Ϫ cells, the deactivation of MAPK occurred later than in NIH3T3 due to a longer cell cycle (K. Baily, unpublished observations). These data demonstrate that although FGF-2(S117A) binds to and activates FGF receptors and stimulates MAPK and p70S6K pathways similar to wild-type FGF-2, it is a poor inducer of proliferation.
FGF-2(S117A) is translocated to the nucleus of cells undergoing G1-S transition
Exogenously added FGF-2 translocates to the nucleus of proliferating cells (22, 26, 54, 55) . We first verified that the stability of FGF-2(S117A) in conditioned culture medium was similar to that of FGF-2(WT) (Fig. 5A) and, by an in vitro assay, that the FGF-2 mutant dimerized as strongly as wild-type growth factor (data not shown). Localization of FGF-2(S117A) was examined by indirect immunofluorescence analysis using an anti-FGF-2 monoclonal antibody in NIH3T3 cells (Fig. 5B) . Bright staining was observed in the nucleus after stimulation of G0-arrested cells by both wild-type and mutated growth factor, with a diffuse staining of the cytoplasm (Fig. 5B, B and D) . In control experiments, no staining was observed when unstimulated cells were exposed to the anti-FGF-2 antibody (Fig. 5B, A) . Confocal sectioning revealed that both wild-type and mutated FGF-2 exhibited an intranuclear localization (Fig. 5B, C and E) . These results indicate that exogenously added FGF-2(S117A) retains its ability of being internalized from outside the cell to the cytoplasm and the nucleus. Moreover, these data show that the inability of FGF-2(S117A) to induce S phase transition is not due to a defect in internalization or transport to the nucleus, but rather probably reflects the inability of the mutated growth factor to interact with the appropriate intracellular targets. 
FGF-2(S117A) is phosphorylated in living cells
Vilgrain et al. (56) have reported the phosphorylation of FGF-2 by kinase distinct from protein kinas A and protein kinase C in the nuclei of human hepatoma cells, suggesting a potential role for this phosphorylation in the regulation of cell growth. The S117A mutation disrupts a consensus phosphorylation site for protein kinase C (␣, ␤, ␥) [(S/T)X(R/ K)] in human FGF-2 (57). Therefore, we compared phosphorylation of FGF-2(S117A) and wild-type FGF-2 in the cytoplasm and nucleus of living cells. NIH3T3 cells were incubated with unlabeled biotinylated FGF-2(WT) and FGF-2(S117A) in the presence of 32 PO 4 3Ϫ . The mutated FGF-2 was labeled in both the nucleus and cytoplasm similar to wild-type growth factor (Fig. 6) . These results rule out the lanes 2-4) or biot-FGF-2(S117A) (lanes 5-7) (20 ng/ml). Then conditioned culture medium was incubated in the presence of streptavidin beads. Proteins bound on streptavidin beads were analyzed by Western blotting using anti-FGF-2 antibody. B) Confocal laser scanning of G0-arrested NIH3T3 cells unstimulated (A) or treated with 20 ng/ml FGF-2(WT) (B, C) or FGF-2(S117A) (D, E) for 4 h. Permeabilized cells were analyzed by indirect immunofluorescence using anti-FGF-2 monoclonal antibody. Immunoblotting with antibodies raised against nonphosphorylated forms of p44 and p42 was performed to verify that equal amounts of cell extracts had been used. B) Lysates from unstimulated or FGF-2(WT) or FGF-2(S117A)-stimulated (60 min) NIH3T3 cells were immunoprecipitated with antip70S6K antibody. The precipitates were incubated in the kinase buffer and [␥ 32 -P]ATP in the presence of substrate peptide and the samples were transferred onto a numbered P81 paper. Incorporation of 32 P into the substrate peptide was quantified by scintillation counter. Quantities of immunoprecipitated p70S6K used in each assay were visualized by blotting with an anti-p70S6K antibody. C) Study of MAPK activation in Emfi fgf-2 Ϫ/Ϫ was performed as described in a.
possibility that a defect in phosphorylation of the growth factor in the cells could be the reason for reduced mitogenicity of FGF-2(S117A). Rather, the data suggest that an intracellular function of FGF-2 is affected by the mutation, probably the activation of a new downstream effector.
FGF-2(S117A) neither binds to nor activates nuclear CK2 in vivo
To test our hypothesis that CK2 could be one of the intracellular targets of exogenous FGF-2, we first isolated CK2/FGF-2 complexes in biotinylated FGF-2(WT) [biot-FGF-2(WT)] or biotinylated FGF-2(S117A) [biot-FGF-2(S117A)] stimulated NIH3T3 cells. As expected, biot-FGF-2(S117A) had a severely reduced capacity to promote G1-S transition in NIH3T3 cells (Fig.  7A) . Four hours after the addition of biot-FGF-2(WT), FGF-2(WT)/CK2 complexes were detected in cytoplasmic and nuclear fractions (Fig. 7B, lanes 2 and 7) . The number of these complexes increased after 12 h of stimulation, which corresponded to the G1/S phase transition of NIH3T3 cell cycle (Fig. 7B, lanes 4 and 9) . In contrast, FGF-2(S117A)/CK2 complexes were poorly detected in cytoplasmic and nuclear fractions (Fig. 7B, lanes 3, 5, 8, and 10 ). FGF-2/CK2 complexes were not detected during the S phase (data not shown). FGF-2(S117A) is poorly detected in the nuclear fraction at the beginning of the S phase of the cell cycle (Fig. 7B, upper panel, lane 10) . Since there was no concomitant increase in FGF-2(S117A) content in Figure 6 . FGF-2(S117A) is phosphorylated in both the cytoplasm and the nucleus. G0-arrested NIH3T3 cells were incubated without (Ϫ) or with 20 ng/ml biotinylated FGF-2(WT) (WT) or biotinylated FGF-2(S117A) (S117A) for 12 h in presence of 32 PO 4 3-. The cells were lysed and nuclear and postnuclear fractions were incubated in the presence of streptavidin beads. Proteins bound on streptavidin beads were analyzed by SDS-PAGE and autoradiography. lanes 2, 4, 7, 9 ) or biot-FGF-2(S117A) (lanes 3, 5, 8, 10) (20 ng/ml). Nuclear and postnuclear fractions were incubated in the presence of streptavidin beads. Proteins bound on streptavidin beads were analyzed by Western blotting using anti-FGF-2 antibody (upper panel), anti-CK2 ␣, and anti-CK2 ␤ antibodies (medium and lower panels). C) Exponentially growing NIH3T3 (lanes 1 and 2) or PC12 cells (lanes 3 and 4) were incubated for 12 h without growth factor (lanes 2 and 4) or with biot-FGF-2(WT) (lanes 1 and 3) (20 ng/ml). Total cellular extracts were incubated in the presence of streptavidin beads. Proteins bound on streptavidin beads were analyzed by Western blotting as described in panel B.
the cytoplasm (Fig. 7B, upper panel, lane 5) , the loss of this mutant in the nucleus was likely due to its nuclear degradation. To support the idea that FGF-2 binding to CK2 is required for cell proliferation, we have looked for the presence of FGF-2/CK2 complexes in PC12 cells. Since these cells differentiate rather than proliferate in response to FGF-2 treatment, we would expect to see a lack of interaction between FGF-2 and CK2 in these cells. As shown Fig. 7C , we did not observe any complexes between FGF-2 and CK2 in total cellular extracts from FGF-2-stimulated PC12 cells. Taken together, these results suggest that this complex formation is required for FGF-2-stimulated cell proliferation.
The activity of CK2 in the cytoplasmic and nuclear fractions from FGF-2-treated cells was then determined. The appearance of FGF-2(WT)/CK2 nuclear complexes was correlated with the stimulation of nuclear CK2 activity (Fig. 8A) . However, the peak of CK2 activity did not correspond to the maximal amount of detected FGF-2/CK2 complexes. Surprisingly, the stimulation of CK2 activity was never observed with cytoplasmic fraction from FGF-2(WT)-stimulated cells. No activation of CK2 in the cytoplasmic and nuclear fractions from FGF-2(S117A)-treated cells was detected. To further study the specificity of CK2 activation by FGF-2, we examined the effect of serum (FCS) on the modulation of CK2 activity (Fig. 8B) . Serum is known to mimic the effects of diverse growth factors. We found that CK2 activity did not increase in nuclear and cytoplasmic extracts from serum-stimulated cells. Thus, in our experimental conditions, FGF-2 specifically activates nuclear CK2 in early G 1 phase.
DISCUSSION
We show in this paper that the mitogenic and differentiation activities of FGF-2 could be uncoupled by a single point mutation (S117A). The FGF-2(S117A) mutant is enable to stimulate DNA synthesis in G0-arrested NIH3T3 and ABAE cells (Fig. 2A) . However, like wild-type FGF-2, this mutant promotes neurite outgrowth in rat PC12 cells and induces epithelial-mesenchymal transition in FGF-R1-transfected bladder carcinoma cells (NBTII.R1 cells) (Fig.  2B) . Neither FGF-2(WT) nor FGF-2(S117A) is able to induce this transition in untransfected cells (NBTII cells), demonstrating that FGF-2(S117A) recognizes the FGF-R1 and induces signaling pathways implicated in the differentiation of NBTII.R1 cells similar to wild-type FGF-2.
FGF-2 exerts its effects in cell growth and differentiation through a dual receptor system in which it is suggested that the low-affinity HSPG molecules may act to deliver FGF to high-affinity tyrosine kinase receptors (8, 58) . The identification of FGF-2 functional domains that participate in binding to heparin and tyrosine kinase receptors (14) implies that the S117 residue is not involved in these interactions. Indeed, our results demonstrate that the mutation S117A does not affect the binding properties of FGF-2 to high-affinity receptors (Fig. 3A) and hepa- rin (data not shown). The interaction of FGF-2 with tyrosine kinase receptors leads to tyrosine phosphorylation of several molecules and to the activation of at least three signaling pathways described to be involved in the mitogenic signal transmission of FGF-2: PLC␥, p70S6K, and MAPK (15, 44) . In agreement with previous studies using different cell types (18, 19) , we show that PLC␥ signaling pathway activation is not involved in mitogenic signal transduction induced by FGF-2 in NIH3T3 cells (data not shown). Although FGF-2(S117A) induced protein tyrosine phosphorylation (Fig. 3B) and activated the MAPK and p70S6K pathway in NIH3T3 cells as did wild-type FGF-2 (Fig. 4A, B) , this mutant was a poor inducer of proliferation. Thus, similar to FGF-1 (23, 24, 59 ), our results demonstrate that activation of tyrosine kinase of FGF receptors, particularly MAPK stimulation, is insufficient to program the cells to enter S phase of the cell cycle. In addition, we show that FGF-2-induced p70S6K activation is insufficient to stimulate cell proliferation too.
It has been shown that FGF-1 and 2 are translocated to the nucleus of cells undergoing G1-S transition (23, 24, 26) . Several authors suggest that signaling events in addition to the activation of FGF-R are necessary to mediate cellular responses by FGFs (24, 59, 60) . Wiedlocha et al. (54, 55, (61) (62) (63) propose a dual mode of signal transduction by externally added FGF-1 involving the stimulation of tyrosine kinase activity of the receptors and nuclear translocation of FGF-1, perhaps via the high-affinity receptors. Transport of FGF-1 to the nucleus is essential for DNA synthesis (23) (24) (25) . It is therefore possible that the translocation of FGF-2 to the nucleus could be relevant to its mitogenic activity. The defect in FGF-2(S117A) mitogenic activity is not due to its inability to be translocated to the nucleus (Fig. 5B) . However, we observed that the mutated growth factor is not seen in the nucleus at 12 h (Fig. 7B,  lane 10 ). This suggests that it is degraded before the G1-S transition. We can speculate that this degradation is a defect in an interaction with appropriate nuclear targets or in its phosphorylation in the nucleus. It has been proposed that phosphorylation of FGF-1 might be important for its mitogenic activity (45) . Since the S117A mutation does not affect the phosphorylation of FGF-2 (Fig. 6) , the lack of interaction with appropriate nuclear target is likely to be responsible for the degradation of the mutated growth factor.
We previously reported that the addition of FGF-2 to isolated nuclei from G0-arrested cells stimulates RNA polymerase I activity and induces the phosphorylation of nucleolin, which is a substrate of CK2 and plays a pivotal role in preribosomal RNA metabolism (22, 47) . In line with these data, several authors described that CK2 or, more specifically, its ␤ subunit, was located mainly in the nucleus of growing cells but spread throughout the cells that are G0-arrested or confluent (64 -66) . Therefore, a coordinated spatio-temporal distribution of FGF-2 and CK2 in the nucleus could allow the regulation of specific nuclear protein phosphorylations, such as nucleolin phosphorylation, during the G1-S transition.
Recently, we have demonstrated that, in vitro, FGF-2 directly stimulates CK2 activity by interacting with its regulatory ␤ subunit. FGF-2 seems to specifically activate this enzyme, since FGF-1, insulin, NGF, and EGF do not directly modulate CK2 activity (29) . Here we show that complexes between FGF-2(WT) and CK2 can be recovered in vivo from the cytosol and the nucleus of cells undergoing G1-S transition (Fig. 7B) . FGF-2/CK2 complexes were not detected during the S phase (data not shown). We observed the stimulation of CK2 by FGF-2 only in the nuclear fraction, and this stimulation reached a maximum in early G 1 phase (4 h after FGF-2 stimulation) (Fig.  8A ). This maximal stimulation of CK2 activity did not correlate with the maximal quantity of complexes, suggesting that a process of CK2 desensitization exists for quenching signal transduction. Altogether, these data suggest that although FGF-2(WT)/CK2 complexes can be found both in the cytoplasm and in the nucleus, only the nuclear ones could be functionally active. Moreover, the stimulation of nuclear CK2 activity in early G 1 phase was not observed with serum (Fig. 8B) , suggesting that the activation of this kinase was specific to FGF-2. Our FGF-2(S117A) mutant impaired in its mitogenic activity did not interact in vivo with CK2. In addition, FGF-2 does not interact with CK2 in PC12 cells in which the growth factor induces a differentiation response rather than a mitogenic one. Taken together, our results raise the possibility that CK2 may be an essential element in nuclear signaling pathway involved in FGF-2-induced mitogenic signal in early G 1 phase.
